Track 50+ health metrics with AI-powered accuracy
She is nuts, Williams laughs
Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
Injections are believed to work better than oral supplements by bypassing the digestive tract
The expression levels of MCT1, MCT4 ( SLC16A4 ), SMCT1 ( SLC5A8 ), and SMCT2 ( SLC5A12 ) vary in different regions of the intestine [78,79,80,81], collectively facilitating the transport of butyrate from the intestinal lumen to the portal vein
The study was approved by the Animal Welfare Committee of the University of Pcs, and the Hungarian National Scientific Ethical Committee on Animal Experimentation
